Timo Gaiser

9PUBLICATIONS
37CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience

|Dec 11, 2022
DNA-Methylation Analysis as a Tool for Thymoma Classification.

Timo Gaiser, Daniela Hirsch, Isabel Porth

|Jun 16, 2022
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.

Ralf-Dieter Hofheinz, Kirsten Merx, Georg M Haag

|Jan 30, 2020
TGF-β2 silencing to target biliary-derived liver diseases.

Anne Dropmann, Steven Dooley, Bedair Dewidar

Pageof 2